piracetam has been researched along with Schizophrenia in 13 studies
Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.
Schizophrenia: A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with levetiracetam dose-dependently improved memory performance of the ketamine-exposed rats." | 5.48 | Treatment with levetiracetam improves cognition in a ketamine rat model of schizophrenia. ( Gallagher, M; Koh, MT; Rosenzweig-Lipson, S; Shao, Y, 2018) |
| "A study of 246 patients (with schizophrenia, manic depressive psychoses and psychoorganic syndrome) treated by some drugs of a metabolic action (encephalotropic", "nootropic" drugs, piracetam, piriditol and pantogam) permitted one to determine the place of these preparations in a comprehensive treatment of mental disorders." | 3.66 | [Certain principles for differential utilization of metabolic treatment preparations in the complex therapy of mental disorders]. ( Avrutskiĭ, GIa; Laskova, NB, 1979) |
| "Piracetam is a potent antioxidant, a cerebral neuroprotector, a neuronal metabolic enhancer, and a brain integrative agent." | 2.73 | Efficacy of piracetam in the treatment of tardive dyskinesia in schizophrenic patients: a randomized, double-blind, placebo-controlled crossover study. ( Bersudsky, Y; Dwolatzky, T; Lerner, V; Libov, I; Miodownik, C, 2007) |
| " Daily dosage of piracetam was 7." | 2.70 | Effect of piracetam on ECT-induced cognitive disturbances: a randomized, placebo-controlled, double-blind study. ( Leung, HC; Tang, WK; Ungvari, GS, 2002) |
| " All patients were kept on continuous psychotropic medication for at least 3 weeks before starting the trial, and piracetam was given additionally in a fixed dosage of 2400 mg daily; the same number of identical capsules was given during the pre- and post-treatment placebo periods." | 2.65 | Biological correlates of piracetam clinical effects in psychotic patients. ( Erban, L; Hanzlicek, L; Kabes, J; Skondia, V, 1979) |
| "Treatment with levetiracetam dose-dependently improved memory performance of the ketamine-exposed rats." | 1.48 | Treatment with levetiracetam improves cognition in a ketamine rat model of schizophrenia. ( Gallagher, M; Koh, MT; Rosenzweig-Lipson, S; Shao, Y, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (53.85) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 3 (23.08) | 29.6817 |
| 2010's | 2 (15.38) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Koh, MT | 1 |
| Shao, Y | 1 |
| Rosenzweig-Lipson, S | 1 |
| Gallagher, M | 1 |
| Lerner, V | 2 |
| Miodownik, C | 2 |
| Tang, WK | 1 |
| Ungvari, GS | 1 |
| Leung, HC | 1 |
| Libov, I | 1 |
| Bersudsky, Y | 1 |
| Dwolatzky, T | 1 |
| Noorbala, AA | 1 |
| Akhondzadeh, S | 1 |
| Davari-Ashtiani, R | 1 |
| Amini-Nooshabadi, H | 1 |
| Fehr, C | 1 |
| Dahmen, N | 1 |
| Klawe, C | 1 |
| Eicke, M | 1 |
| Szegedi, A | 1 |
| Dimond, SJ | 1 |
| Scammell, RE | 1 |
| Pryce, IG | 3 |
| Huws, D | 1 |
| Gray, C | 2 |
| Avrutskiĭ, GIa | 1 |
| Laskova, NB | 1 |
| Kabes, J | 1 |
| Erban, L | 1 |
| Hanzlicek, L | 1 |
| Skondia, V | 1 |
| Tacke, B | 1 |
| Freistein, H | 1 |
| Kempf, H | 1 |
| Windheuser, A | 1 |
| Wilsher, CR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Therapeutic Use of Piracetam for Treatment of Patients Suffering From Tardive Dyskinesia: a Double Blind, Placebo-Controlled Crossover Study[NCT00190008] | Phase 3 | 40 participants | Interventional | 2003-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for piracetam and Schizophrenia
| Article | Year |
|---|---|
Motor symptoms of schizophrenia: is tardive dyskinesia a symptom or side effect? A modern treatment.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Fatty Acids, Omega-3; Ginkgo biloba; Humans; Levetira | 2011 |
Effects of piracetam on developmental dyslexia.
Topics: Animals; Cerebral Cortex; Clinical Trials as Topic; Conditioning, Operant; Corpus Callosum; Dogs; Do | 1986 |
8 trials available for piracetam and Schizophrenia
| Article | Year |
|---|---|
Effect of piracetam on ECT-induced cognitive disturbances: a randomized, placebo-controlled, double-blind study.
Topics: Adult; Depression; Double-Blind Method; Electroconvulsive Therapy; Female; Humans; Male; Memory Diso | 2002 |
Efficacy of piracetam in the treatment of tardive dyskinesia in schizophrenic patients: a randomized, double-blind, placebo-controlled crossover study.
Topics: Administration, Oral; Adult; Aged; Cross-Over Studies; Double-Blind Method; Dyskinesia, Drug-Induced | 2007 |
Piracetam in the treatment of schizophrenia: implications for the glutamate hypothesis of schizophrenia.
Topics: Adolescent; Adult; Analysis of Variance; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Co | 1999 |
Some effects of piracetam (UCB 6215, Nootropyl) on chronic schizophrenia.
Topics: Adult; Chronic Disease; Clinical Trials as Topic; Dichotic Listening Tests; Double-Blind Method; Fem | 1979 |
Trial of 'Piracetam' in chronic schizophrenia.
Topics: Chronic Disease; Clinical Trials as Topic; Double-Blind Method; Humans; Piracetam; Pyrrolidinones; S | 1978 |
Biological correlates of piracetam clinical effects in psychotic patients.
Topics: Adenosine Diphosphate; Adenosine Triphosphate; Adult; Depression; Drug Therapy, Combination; Energy | 1979 |
[Pilot study of 2-pyrrolidon-acetamid (generic name: piracetam) (author's transl)].
Topics: Adult; Chemical Phenomena; Chemistry; Clinical Trials as Topic; Drug Evaluation; Humans; Middle Aged | 1975 |
Effects of piracetam on developmental dyslexia.
Topics: Animals; Cerebral Cortex; Clinical Trials as Topic; Conditioning, Operant; Corpus Callosum; Dogs; Do | 1986 |
4 other studies available for piracetam and Schizophrenia
| Article | Year |
|---|---|
Treatment with levetiracetam improves cognition in a ketamine rat model of schizophrenia.
Topics: Amphetamine; Animals; Central Nervous System Stimulants; Cognition Disorders; Disease Models, Animal | 2018 |
Piracetam in the treatment of tardive dyskinesia and akathisia: a case report.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Dyskinesia, Drug-Induced; Haloperidol; Humans; | 2001 |
[Certain principles for differential utilization of metabolic treatment preparations in the complex therapy of mental disorders].
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Brain Injuries; gamma-Aminobutyric Acid; Humans; Infectio | 1979 |
Clinical research upon mentally ill subjects who cannot give informed consent.
Topics: Ethics, Medical; Human Experimentation; Humans; Informed Consent; Mental Disorders; Piracetam; Resea | 1978 |